Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany
Background Neurological disorders with IgG antibodies against myelin-oligodendrocyte glycoprotein (MOG-IgG) have been increasingly recognised as a new type of neuroinflammatory disorder. - Objective The study aimed to identify regional and ethnic differences in clinical profiles of MOG-IgG-associate...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2021
|
| In: |
Journal of neurology, neurosurgery, and psychiatry
Year: 2021, Volume: 92, Issue: 4, Pages: 377-383 |
| ISSN: | 1468-330X |
| DOI: | 10.1136/jnnp-2020-324422 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/jnnp-2020-324422 Verlag, lizenzpflichtig, Volltext: https://jnnp.bmj.com/content/92/4/377 
|
| Author Notes: | Jia Liu, Masahiro Mori, Hanna Zimmermann, Alexander Brandt, Joachim Havla, Satoru Tanaka, Kazuo Sugimoto, Satoru Oji, Akiyuki Uzawa, Susanna Asseyer, Graham Cooper, Sven Jarius, Judith Bellmann-Strobl, Klemens Ruprecht, Nadja Siebert, Hiroki Masuda, Tomohiko Uchida, Ryohei Ohtani, Kyoichi Nomura, Edgar Meinl, Tania Kuempfel, Friedemann Paul, Satoshi Kuwabara |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1756558736 | ||
| 003 | DE-627 | ||
| 005 | 20230426092538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210429s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jnnp-2020-324422 |2 doi | |
| 035 | |a (DE-627)1756558736 | ||
| 035 | |a (DE-599)KXP1756558736 | ||
| 035 | |a (OCoLC)1341407283 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Liu, Jia |e VerfasserIn |0 (DE-588)1233349457 |0 (DE-627)1757682988 |4 aut | |
| 245 | 1 | 0 | |a Anti-MOG antibody-associated disorders |b differences in clinical profiles and prognosis in Japan and Germany |c Jia Liu, Masahiro Mori, Hanna Zimmermann, Alexander Brandt, Joachim Havla, Satoru Tanaka, Kazuo Sugimoto, Satoru Oji, Akiyuki Uzawa, Susanna Asseyer, Graham Cooper, Sven Jarius, Judith Bellmann-Strobl, Klemens Ruprecht, Nadja Siebert, Hiroki Masuda, Tomohiko Uchida, Ryohei Ohtani, Kyoichi Nomura, Edgar Meinl, Tania Kuempfel, Friedemann Paul, Satoshi Kuwabara |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online first 20 November 2020 | ||
| 500 | |a Gesehen am 30.07.2021 | ||
| 520 | |a Background Neurological disorders with IgG antibodies against myelin-oligodendrocyte glycoprotein (MOG-IgG) have been increasingly recognised as a new type of neuroinflammatory disorder. - Objective The study aimed to identify regional and ethnic differences in clinical profiles of MOG-IgG-associated disorders between East Asian (Japanese) and Caucasian (German) patients. - Methods Demographic, clinical and therapeutic data from 68 MOG-IgG-positive adults were collected (Japanese, n=44; German, n=24). - Results Age and sex were similar between cohorts, with optic neuritis occurring most frequently at onset (Japanese: 61%; German: 58%). However, Japanese patients had a lower annualised relapse rate (0.4 vs 0.8, p=0.019; no relapse, 64% vs 25%, p=0.002) and lower Expanded Disability Status Scale score at the last visit (1.0 vs 2.0; p=0.008), despite similar follow-up periods (mean, 73.9 months vs 73.4 months), than those of German patients, respectively. Cerebral syndromes were more common (27% vs 4%; p=0.021) and myelitis less common (21% vs 50%; p=0.012) in Japanese than in German patients, respectively. Japanese patients were more commonly treated with long-term corticosteroids (73%), whereas German patients were more commonly treated with rituximab or other immunosuppressants (63%). - Conclusions Among patients with MOG-IgG, Japanese tended to have a monophasic milder disease, whereas the majority of German patients had a relapsing course and more frequent myelitis, findings compatible with neuromyelitis optica spectrum disorder. Although the attack-prevention treatment regimens were considerably different, genetic and environmental factors may be important to determine clinical phenotypes and disease activity. | ||
| 700 | 1 | |a Mori, Masahiro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zimmermann, Hanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brandt, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Havla, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tanaka, Satoru |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sugimoto, Kazuo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oji, Satoru |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uzawa, Akiyuki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Asseyer, Susanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cooper, Graham |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jarius, Sven |e VerfasserIn |0 (DE-588)1054615918 |0 (DE-627)791654818 |0 (DE-576)410367478 |4 aut | |
| 700 | 1 | |a Bellmann-Strobl, Judith |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ruprecht, Klemens |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siebert, Nadja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Masuda, Hiroki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uchida, Tomohiko |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ohtani, Ryohei |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nomura, Kyoichi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Meinl, Edgar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuempfel, Tania |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paul, Friedemann |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuwabara, Satoshi |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology, neurosurgery, and psychiatry |d London : BMJ Publishing Group, 1944 |g 92(2021), 4, Seite 377-383 |h Online-Ressource |w (DE-627)271594691 |w (DE-600)1480429-3 |w (DE-576)078707617 |x 1468-330X |7 nnas |a Anti-MOG antibody-associated disorders differences in clinical profiles and prognosis in Japan and Germany |
| 773 | 1 | 8 | |g volume:92 |g year:2021 |g number:4 |g pages:377-383 |a Anti-MOG antibody-associated disorders differences in clinical profiles and prognosis in Japan and Germany |
| 856 | 4 | 0 | |u https://doi.org/10.1136/jnnp-2020-324422 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://jnnp.bmj.com/content/92/4/377 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210429 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1054615918 |a Jarius, Sven |m 1054615918:Jarius, Sven |d 910000 |d 911100 |e 910000PJ1054615918 |e 911100PJ1054615918 |k 0/910000/ |k 1/910000/911100/ |p 12 | ||
| 999 | |a KXP-PPN1756558736 |e 391974554X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"name":{"displayForm":["Jia Liu, Masahiro Mori, Hanna Zimmermann, Alexander Brandt, Joachim Havla, Satoru Tanaka, Kazuo Sugimoto, Satoru Oji, Akiyuki Uzawa, Susanna Asseyer, Graham Cooper, Sven Jarius, Judith Bellmann-Strobl, Klemens Ruprecht, Nadja Siebert, Hiroki Masuda, Tomohiko Uchida, Ryohei Ohtani, Kyoichi Nomura, Edgar Meinl, Tania Kuempfel, Friedemann Paul, Satoshi Kuwabara"]},"person":[{"role":"aut","given":"Jia","family":"Liu","display":"Liu, Jia"},{"display":"Mori, Masahiro","family":"Mori","given":"Masahiro","role":"aut"},{"display":"Zimmermann, Hanna","role":"aut","given":"Hanna","family":"Zimmermann"},{"display":"Brandt, Alexander","family":"Brandt","given":"Alexander","role":"aut"},{"display":"Havla, Joachim","role":"aut","given":"Joachim","family":"Havla"},{"display":"Tanaka, Satoru","role":"aut","given":"Satoru","family":"Tanaka"},{"family":"Sugimoto","role":"aut","given":"Kazuo","display":"Sugimoto, Kazuo"},{"role":"aut","given":"Satoru","family":"Oji","display":"Oji, Satoru"},{"family":"Uzawa","role":"aut","given":"Akiyuki","display":"Uzawa, Akiyuki"},{"display":"Asseyer, Susanna","family":"Asseyer","given":"Susanna","role":"aut"},{"role":"aut","given":"Graham","family":"Cooper","display":"Cooper, Graham"},{"display":"Jarius, Sven","given":"Sven","role":"aut","family":"Jarius"},{"role":"aut","given":"Judith","family":"Bellmann-Strobl","display":"Bellmann-Strobl, Judith"},{"family":"Ruprecht","role":"aut","given":"Klemens","display":"Ruprecht, Klemens"},{"display":"Siebert, Nadja","family":"Siebert","given":"Nadja","role":"aut"},{"display":"Masuda, Hiroki","family":"Masuda","role":"aut","given":"Hiroki"},{"family":"Uchida","given":"Tomohiko","role":"aut","display":"Uchida, Tomohiko"},{"display":"Ohtani, Ryohei","family":"Ohtani","role":"aut","given":"Ryohei"},{"family":"Nomura","given":"Kyoichi","role":"aut","display":"Nomura, Kyoichi"},{"display":"Meinl, Edgar","given":"Edgar","role":"aut","family":"Meinl"},{"given":"Tania","role":"aut","family":"Kuempfel","display":"Kuempfel, Tania"},{"family":"Paul","given":"Friedemann","role":"aut","display":"Paul, Friedemann"},{"display":"Kuwabara, Satoshi","family":"Kuwabara","role":"aut","given":"Satoshi"}],"relHost":[{"id":{"zdb":["1480429-3"],"issn":["1468-330X"],"eki":["271594691"]},"part":{"pages":"377-383","year":"2021","text":"92(2021), 4, Seite 377-383","volume":"92","issue":"4"},"titleAlt":[{"title":"JNNP online"},{"title":"Journal of neurology, neurosurgery & psychiatry"}],"pubHistory":["N.S. 7.1944,3 - 42.1979; 43.1980 -"],"corporate":[{"role":"isb","display":"British Medical Association"}],"disp":"Anti-MOG antibody-associated disorders differences in clinical profiles and prognosis in Japan and GermanyJournal of neurology, neurosurgery, and psychiatry","recId":"271594691","physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"a peer review journal for health professionals and researchers in all areas of neurology","title_sort":"Journal of neurology, neurosurgery, and psychiatry","title":"Journal of neurology, neurosurgery, and psychiatry"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 30.11.12","Beteil. Körp. früher: British Medical Association"],"origin":[{"publisher":"BMJ Publishing Group","dateIssuedDisp":"1944-","dateIssuedKey":"1944","publisherPlace":"London"}]}],"id":{"doi":["10.1136/jnnp-2020-324422"],"eki":["1756558736"]},"title":[{"subtitle":"differences in clinical profiles and prognosis in Japan and Germany","title_sort":"Anti-MOG antibody-associated disorders","title":"Anti-MOG antibody-associated disorders"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Published online first 20 November 2020","Gesehen am 30.07.2021"],"recId":"1756558736"} | ||
| SRT | |a LIUJIAMORIANTIMOGANT2021 | ||